300294 博雅生物
交易中 07-01 14:01:36
资讯
新帖
简况
博雅生物:坚持长期主义,聚焦主业提升经营质量与盈利能力
证券之星 · 06-30 16:06
博雅生物:坚持长期主义,聚焦主业提升经营质量与盈利能力
博雅生物:持续深耕血液制品主业
证券之星 · 06-30 16:03
博雅生物:持续深耕血液制品主业
博雅生物(300294)披露转让南京新百药业100%股权进展暨完成工商变更登记公告,6月25日股价下跌2.99%
证券之星 · 06-25
博雅生物(300294)披露转让南京新百药业100%股权进展暨完成工商变更登记公告,6月25日股价下跌2.99%
博雅生物:紧紧围绕“技术、人才、品牌、效率、机制”五大核心要素
证券之星 · 06-24
博雅生物:紧紧围绕“技术、人才、品牌、效率、机制”五大核心要素
博雅生物:公司2026年6月18日股东人数为31,204户
证券之星 · 06-24
博雅生物:公司2026年6月18日股东人数为31,204户
博雅生物(300294)披露2026年度董事、高级管理人员薪酬方案,6月23日股价上涨1.83%
证券之星 · 06-23
博雅生物(300294)披露2026年度董事、高级管理人员薪酬方案,6月23日股价上涨1.83%
股市必读:博雅生物(300294)6月18日董秘有最新回复
证券之星 · 06-22
股市必读:博雅生物(300294)6月18日董秘有最新回复
每周股票复盘:博雅生物(300294)独立董事辞任待补选,两家子公司完成更名
证券之星 · 06-21
每周股票复盘:博雅生物(300294)独立董事辞任待补选,两家子公司完成更名
博雅生物:南京新百药业正在办理股权转让工商登记的相关手续
证券之星 · 06-18
博雅生物:南京新百药业正在办理股权转让工商登记的相关手续
博雅生物(300294)披露独立董事辞任公告,6月16日股价下跌1.68%
证券之星 · 06-16
博雅生物(300294)披露独立董事辞任公告,6月16日股价下跌1.68%
博雅生物:公司2026年6月10日含信用账户合并名册的股东人数为31,943户
证券之星 · 06-11
博雅生物:公司2026年6月10日含信用账户合并名册的股东人数为31,943户
博雅生物:静注人免疫球蛋白已获得多米尼加、巴基斯坦的注册证书
证券之星 · 06-09
博雅生物:静注人免疫球蛋白已获得多米尼加、巴基斯坦的注册证书
博雅生物:公司2026年5月29日含信用账户合并名册的股东人数为32,756户
证券之星 · 06-04
博雅生物:公司2026年5月29日含信用账户合并名册的股东人数为32,756户
博雅生物:坚持长期主义,聚焦主业,提升经营质量与盈利能力
证券之星 · 06-04
博雅生物:坚持长期主义,聚焦主业,提升经营质量与盈利能力
博雅生物:公司已建立完善且运行成熟的战略决策、经营管理体系
证券之星 · 06-03
博雅生物:公司已建立完善且运行成熟的战略决策、经营管理体系
博雅生物:2026 年一季度,公司采浆业务有序推进,采浆规模同比保持稳健增长
证券之星 · 06-02
博雅生物:2026 年一季度,公司采浆业务有序推进,采浆规模同比保持稳健增长
博雅生物:公司生产经营情况稳定
证券之星 · 06-02
博雅生物:公司生产经营情况稳定
博雅生物:坚持长期主义,聚焦主业,提升经营质量与盈利能力
证券之星 · 06-02
博雅生物:坚持长期主义,聚焦主业,提升经营质量与盈利能力
股市必读:博雅生物(300294)5月29日董秘有最新回复
证券之星 · 06-01
股市必读:博雅生物(300294)5月29日董秘有最新回复
博雅生物:今年公司产品尚未在巴西销售
证券之星 · 05-29
博雅生物:今年公司产品尚未在巴西销售
加载更多
公司概况
公司名称:
华润博雅生物制药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-03-08
主营业务:
华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白(含10%高浓度剂型)、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚,先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项,拥有各类专利200余项,多次荣膺省、市科学技术奖和优秀新产品奖。
发行价格:
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":14.85,"timestamp":1782885696000,"preClose":14.24,"halted":0,"volume":6372608,"delay":0,"changeRate":0.0428,"floatShares":504000000,"shares":504000000,"eps":0.0069,"marketStatus":"交易中","change":0.61,"latestTime":"07-01 14:01:36","open":14.19,"high":14.93,"low":14.09,"amount":92640800,"amplitude":0.059,"askPrice":14.85,"askSize":36,"bidPrice":14.84,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.0069,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782889200000},"marketStatusCode":2,"adr":0,"adjPreClose":14.24,"symbolType":"stock","openAndCloseTimeList":[[1782869400000,1782876600000],[1782882000000,1782889200000]],"highLimit":15.66,"lowLimit":12.82,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":0.96,"roa":"--","peRate":2152.173913,"roe":"0.41%","epsLYR":0.22,"committee":-0.716172,"marketValue":7488000000,"turnoverRate":0.0126,"status":0,"floatMarketCap":7488000000},"requestUrl":"/m/hq/s/300294","defaultTab":"news","newsList":[{"id":"2647535550","title":"博雅生物:坚持长期主义,聚焦主业提升经营质量与盈利能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647535550?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:06","pubTimestamp":1782806788,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问:博雅生物股价已跌破每股净资产,市值马上不足70亿,请问公司管理层是否有预案和对策应对这样的不利局面博雅生物回复:您好,感谢您对本公司的关注。公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。公司一直坚持长期主义,紧紧围绕战略目标,聚焦主业,强化核心竞争力,结合政策环境、市场环境等制定适合公司发展的经营策略,努力做好经营管理,提升经营质量与盈利能力,促进公司健康可持续发展。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535817","title":"博雅生物:持续深耕血液制品主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647535817?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:03","pubTimestamp":1782806600,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问:这场寒冬,既是挑战也是机遇,它会淘汰那些只会躺着赚钱的惰性企业,也会催生具备产品创新能力和精细化管理水平的优质公司。请问博雅如何找到新的增长引擎?博雅生物回复:您好,感谢您对本公司的关注。公司将始终围绕战略目标,持续深耕血液制品主业,多措并举夯实发展根基,聚焦血浆、营销、研发、国际化等核心业务领域,持续蓄力厚植增长动能,提升综合竞争力。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809465","title":"博雅生物(300294)披露转让南京新百药业100%股权进展暨完成工商变更登记公告,6月25日股价下跌2.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646809465?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:35","pubTimestamp":1782398118,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘,博雅生物报收于14.59元,较前一交易日下跌2.99%,最新总市值为73.57亿元。近日,博雅生物披露《关于转让南京新百药业有限公司100%股权进展暨完成工商变更登记的公告》。公告显示,华润博雅生物制药集团股份有限公司于2026年4月23日召开董事会,审议通过将南京新百药业有限公司100%股权转让给华润双鹤药业股份有限公司的议案,交易金额为23,545.62万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0114","BK0070","300294","600682","BK0046","BK0060","BK0113","BK0197","BK0209","BK0183","BK0239","BK0093","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645860891","title":"博雅生物:紧紧围绕“技术、人才、品牌、效率、机制”五大核心要素","url":"https://stock-news.laohu8.com/highlight/detail?id=2645860891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645860891?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:07","pubTimestamp":1782284835,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:华润入主博雅这些年来,董秘觉得企业在维护投资者信心方面做得怎么样?还有哪些可以改进的?博雅生物回复:您好,非常感谢您对本公司的关注。面对行业周期下行,公司上下树立危机意识、凝聚战略共识,紧紧围绕“技术、人才、品牌、效率、机制”五大核心要素,苦练内功,打造五大能力,以提升核心竞争力!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400022176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645384860","title":"博雅生物:公司2026年6月18日股东人数为31,204户","url":"https://stock-news.laohu8.com/highlight/detail?id=2645384860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645384860?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:07","pubTimestamp":1782284835,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘公司最新的股东人数是多少?谢谢。博雅生物回复:您好,感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据,公司2026年6月18日含信用账户合并名册的股东人数为31,204户。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400022172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645832714","title":"博雅生物(300294)披露2026年度董事、高级管理人员薪酬方案,6月23日股价上涨1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645832714","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645832714?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:27","pubTimestamp":1782224842,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘,博雅生物报收于15.54元,较前一交易日上涨1.83%,最新总市值为78.36亿元。该股当日开盘15.17元,最高16.0元,最低15.16元,成交额达9090.52万元,换手率为1.16%。近日,华润博雅生物制药集团股份有限公司发布2026年度董事、高级管理人员薪酬方案。薪酬方案自股东会审议通过之日起生效,实际发放金额依据考评结果确定,并依法代扣代缴税费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645301537","title":"股市必读:博雅生物(300294)6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645301537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645301537?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:48","pubTimestamp":1782067692,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,博雅生物报收于15.68元,下跌1.32%,换手率1.26%,成交量6.34万手,成交额9989.6万元。董秘最新回复投资者: 你好,公司出售南京新百药业当前进展如何?能在上半年按时完成吗?截至目前,南京新百药业正在办理股权转让工商登记的相关手续。当日关注点交易信息汇总:6月18日主力资金净流出1213.72万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200000989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645909524","title":"每周股票复盘:博雅生物(300294)独立董事辞任待补选,两家子公司完成更名","url":"https://stock-news.laohu8.com/highlight/detail?id=2645909524","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645909524?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:18","pubTimestamp":1781979494,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,博雅生物报收于15.68元,较上周的16.75元下跌6.39%。本周关注点公司公告汇总:独立董事赵利因个人原因辞任,待股东会选举新任后生效。公司公告汇总关于公司独立董事辞任的公告华润博雅生物制药集团股份有限公司董事会近日收到独立董事赵利先生提交的书面《辞任报告》。在此之前,赵利先生将继续履行独立董事职责。截至公告日,赵利先生未持有公司股份,无未履行承诺事项,其辞任不影响公司正常运营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644705805","title":"博雅生物:南京新百药业正在办理股权转让工商登记的相关手续","url":"https://stock-news.laohu8.com/highlight/detail?id=2644705805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644705805?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:09","pubTimestamp":1781770159,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,公司出售南京新百药业当前进展如何?能在上半年按时完成吗?博雅生物回复:感谢您对本公司的关注。截至目前,南京新百药业正在办理股权转让工商登记的相关手续。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800026471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","300294","BK0046","BK0042","BK0060","BK0183","BK0070","BK0093","BK0239","BK0113","BK0196","BK0209","BK0197","600682"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643675630","title":"博雅生物(300294)披露独立董事辞任公告,6月16日股价下跌1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643675630","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643675630?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:28","pubTimestamp":1781605726,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,博雅生物报收于16.39元,较前一交易日下跌1.68%,最新总市值为82.65亿元。公告显示,华润博雅生物制药集团股份有限公司董事会于2026年6月15日收到独立董事赵利先生提交的书面《辞任报告》。在此前,赵利先生将继续履行独立董事职责。截至公告日,赵利先生未持有公司股份,无未履行承诺事项,其辞任不影响公司正常运营。公司对赵利先生任职期间的贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600033953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642400923","title":"博雅生物:公司2026年6月10日含信用账户合并名册的股东人数为31,943户","url":"https://stock-news.laohu8.com/highlight/detail?id=2642400923","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642400923?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:57","pubTimestamp":1781168233,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截至2026年6月10日公司股东人数是多少?谢谢。博雅生物回复:您好,感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据,公司2026年6月10日含信用账户合并名册的股东人数为31,943户。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100026388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642654004","title":"博雅生物:静注人免疫球蛋白已获得多米尼加、巴基斯坦的注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642654004","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642654004?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:18","pubTimestamp":1780996712,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月09日在投资者关系平台上答复投资者关心的问题。投资者提问:博雅生物国际化怎么做,有哪些突破博雅生物回复:您好,感谢您对本公司的关注。公司持续推进“引进来、走出去、强合作”的国际化战略,多元探索、多路并进,以全球化视野擘画发展新格局。静注人免疫球蛋白已获得多米尼加、巴基斯坦的注册证书。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900028058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155248","title":"博雅生物:公司2026年5月29日含信用账户合并名册的股东人数为32,756户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155248?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:24","pubTimestamp":1780565078,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘,博雅生物截至2026年5月29日股东人数是多少?谢谢。博雅生物回复:您好,感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据,公司2026年5月29日含信用账户合并名册的股东人数为32,756户。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400030340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640552511","title":"博雅生物:坚持长期主义,聚焦主业,提升经营质量与盈利能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2640552511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640552511?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:24","pubTimestamp":1780565077,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:博雅生物在华润收购后怎一路下跌啊,华润新的班子有提升计划吗博雅生物回复:您好,感谢您对本公司的关注。公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。公司一直坚持长期主义,紧紧围绕战略目标,聚焦主业,强化核心竞争力,结合政策环境、市场环境等制定适合公司发展的经营策略,努力做好经营管理,提升经营质量与盈利能力,促进公司健康可持续发展。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400030338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640086904","title":"博雅生物:公司已建立完善且运行成熟的战略决策、经营管理体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2640086904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640086904?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:52","pubTimestamp":1780491145,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,公司章程规定总裁主持公司的生产经营管理工作、组织实施董事会决议等,现在总裁空缺,公司经验正常吗,管理层是否能有效决策?博雅生物回复:您好,感谢您对本公司的关注。公司已建立完善且运行成熟的战略决策、经营管理体系,本次管理层人员调整,不影响公司既定发展战略与日常经营开展。公司将不断夯实公司治理基础、提升治理水平,多措并举推动公司稳健发展。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300044429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640167729","title":"博雅生物:2026 年一季度,公司采浆业务有序推进,采浆规模同比保持稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2640167729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640167729?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:09","pubTimestamp":1780391346,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问:您好:博雅生物2026年第一季采液量是多少啊博雅生物回复:您好,感谢您对本公司的关注。2026 年一季度,公司采浆业务有序推进,采浆规模同比保持稳健增长。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640916742","title":"博雅生物:公司生产经营情况稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2640916742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640916742?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:09","pubTimestamp":1780391345,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问:近90天国际竞品价格是否有上涨?上涨幅度是多少?博雅生物回复:您好,感谢您对本公司的关注。公司生产经营情况稳定,产品价格随市场供需变化等情况产生波动。公司根据市场环境变化制定相应的价格策略。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640691629","title":"博雅生物:坚持长期主义,聚焦主业,提升经营质量与盈利能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2640691629","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640691629?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:06","pubTimestamp":1780391176,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物06月02日在投资者关系平台上答复投资者关心的问题。投资者提问:根据公开市场信息估算,截至2025年5月,华润医药持有博雅生物的综合加权平均持仓成本约为34.20元/股。公司一直坚持长期主义,紧紧围绕战略目标,聚焦主业,强化核心竞争力,结合政策环境、市场环境等制定适合公司发展的经营策略,努力做好经营管理,提升经营质量与盈利能力,促进公司健康可持续发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640868029","title":"股市必读:博雅生物(300294)5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640868029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640868029?lang=zh_cn&edition=full","pubTime":"2026-06-01 04:40","pubTimestamp":1780260021,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,博雅生物报收于16.49元,上涨7.15%,换手率3.81%,成交量19.2万手,成交额3.15亿元。董秘最新回复投资者: 请问管理层血制品拐点何时到来?当日关注点来自交易信息汇总:5月29日主力资金净流入162.47万元,游资积极介入,散户资金呈净流出态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639762584","title":"博雅生物:今年公司产品尚未在巴西销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2639762584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639762584?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:11","pubTimestamp":1780045887,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问:国外血制品除了人血白蛋白其他产品价格远远高于国内,请问董秘博雅生物是否有对巴西的血制品销售?金额有多少?博雅生物回复:您好,感谢您对本公司的关注。今年公司产品尚未在巴西销售。公司充分评估国际血液制品市场机会,持续推进产品国际注册事宜。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900031650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","159100","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782885700958,"stockEarnings":[{"period":"1week","weight":-0.0837},{"period":"1month","weight":-0.1364},{"period":"3month","weight":-0.2519},{"period":"6month","weight":-0.3671},{"period":"1year","weight":-0.4463},{"period":"ytd","weight":-0.3671}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0369},{"period":"6month","weight":0.0316},{"period":"1year","weight":0.1887},{"period":"ytd","weight":0.0316}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31204人(较上一季度减少2.31%)","perCapita":"16159股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":" 华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白(含10%高浓度剂型)、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚,先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项,拥有各类专利200余项,多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}